Kura Oncology (KURA) Total Liabilities (2010 - 2026)
Kura Oncology (KURA) posted quarterly Total Liabilities of $544.7 million for Q1 2026, up 43.58% year-over-year from $379.4 million in Q1 2025, and down 3.47% quarter-over-quarter from $564.2 million in Q4 2025.
Kura Oncology (KURA) Total Liabilities (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Total Liabilities for 17 consecutive years, with $544.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 43.58% year-over-year to $544.7 million; the TTM figure through Mar 2026 stood at $544.7 million (up 43.58% YoY), while the FY2025 annual figure was $564.2 million, up 62.83% from the prior year.
- Total Liabilities retreated to $544.7 million in Q1 2026 per KURA's latest filing, from $564.2 million in the prior quarter.
- Across five years, Total Liabilities topped out at $564.2 million in Q4 2025 and bottomed at $21.9 million in Q2 2022.
- Historically, Total Liabilities has averaged $178.9 million across 5 years, with a median of $49.0 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities tumbled 34.84% — and 2025, when it soared 676.99%.
- Kura Oncology's Total Liabilities stood at $36.0 million in 2022, then surged by 43.39% to $51.7 million in 2023, then soared by 570.74% to $346.5 million in 2024, then jumped by 62.83% to $564.2 million in 2025, then slipped by 3.47% to $544.7 million in 2026.
- Business Quant data shows KURA's Total Liabilities at $544.7 million in Q1 2026, $564.2 million in Q4 2025, and $406.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 539.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 539.36 Mn |
| Mar 31, 2026 | 544.67 Mn |
| Dec 31, 2025 | 564.23 Mn |
| Sep 30, 2025 | 406.84 Mn |
| Jun 30, 2025 | 376.94 Mn |
| Mar 31, 2025 | 379.36 Mn |
| Dec 31, 2024 | 346.52 Mn |
| Sep 30, 2024 | 55.07 Mn |
| Jun 30, 2024 | 49.05 Mn |
| Mar 31, 2024 | 48.82 Mn |
| Dec 31, 2023 | 51.66 Mn |
| Sep 30, 2023 | 43.83 Mn |
| Jun 30, 2023 | 35.06 Mn |
| Mar 31, 2023 | 30.79 Mn |
| Dec 31, 2022 | 36.03 Mn |
| Sep 30, 2022 | 28.37 Mn |
| Jun 30, 2022 | 21.93 Mn |
| Mar 31, 2022 | 22.34 Mn |
| Dec 31, 2021 | 27.44 Mn |
| Sep 30, 2021 | 27.39 Mn |